DK0900200T5 - Farmaceutiske sammensætninger til forebyggelse og behandling af sygdom i centralnervesystemet - Google Patents

Farmaceutiske sammensætninger til forebyggelse og behandling af sygdom i centralnervesystemet

Info

Publication number
DK0900200T5
DK0900200T5 DK97921232T DK97921232T DK0900200T5 DK 0900200 T5 DK0900200 T5 DK 0900200T5 DK 97921232 T DK97921232 T DK 97921232T DK 97921232 T DK97921232 T DK 97921232T DK 0900200 T5 DK0900200 T5 DK 0900200T5
Authority
DK
Denmark
Prior art keywords
nervous system
central nervous
prevention
treatment
pharmaceutical compositions
Prior art date
Application number
DK97921232T
Other languages
Danish (da)
English (en)
Other versions
DK0900200T3 (da
Inventor
William Scott Caldwell
Gary Maurice Dull
Grayland Page Dobson
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24532629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0900200(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Targacept Inc filed Critical Targacept Inc
Application granted granted Critical
Publication of DK0900200T3 publication Critical patent/DK0900200T3/da
Publication of DK0900200T5 publication Critical patent/DK0900200T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK97921232T 1996-04-23 1997-04-16 Farmaceutiske sammensætninger til forebyggelse og behandling af sygdom i centralnervesystemet DK0900200T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63176196A 1996-04-23 1996-04-23
PCT/US1997/006398 WO1997040011A1 (fr) 1996-04-23 1997-04-16 Preparations pharmaceutiques pour la prevention et le traitement de troubles du systeme nerveux central

Publications (2)

Publication Number Publication Date
DK0900200T3 DK0900200T3 (da) 2009-03-30
DK0900200T5 true DK0900200T5 (da) 2010-01-11

Family

ID=24532629

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97921232T DK0900200T5 (da) 1996-04-23 1997-04-16 Farmaceutiske sammensætninger til forebyggelse og behandling af sygdom i centralnervesystemet

Country Status (12)

Country Link
US (2) US6603011B1 (fr)
EP (2) EP0900200B9 (fr)
JP (2) JP4357001B2 (fr)
AT (1) ATE416164T1 (fr)
AU (1) AU727976B2 (fr)
BR (1) BR9708815B1 (fr)
CA (1) CA2252515C (fr)
DE (1) DE69739142D1 (fr)
DK (1) DK0900200T5 (fr)
ES (1) ES2318856T4 (fr)
PT (1) PT900200E (fr)
WO (1) WO1997040011A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020052497A1 (en) 2000-03-09 2002-05-02 Targacept, Inc. Compounds capable of activating cholinergic receptors
US6166048A (en) * 1999-04-20 2000-12-26 Targacept, Inc. Pharmaceutical compositions for inhibition of cytokine production and secretion
US6979695B2 (en) 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
EP1068186A2 (fr) * 1998-04-02 2001-01-17 Targacept, Inc. Preparations pharmaceutiques et leur modes d'utilisation
US7790757B2 (en) * 1998-06-16 2010-09-07 Targacept, Inc. Compounds capable of activating cholinergic receptors
JP4240815B2 (ja) * 1998-06-16 2009-03-18 ターガセプト，インコーポレイテッド アリール置換オレフィンアミンと、コリン受容体アゴニストとしてのアリール置換オレフィンアミンの使用
US6232316B1 (en) 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
US20050131034A1 (en) 1998-06-16 2005-06-16 Caldwell William S. Compounds capable of activating cholinergic receptors
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
AU2005201609B2 (en) * 1999-04-20 2007-10-18 Targacept, Inc Pharmaceutical compositions for inhibition of cytokine production and secretion
US20010031771A1 (en) 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
JP2003501416A (ja) * 1999-06-07 2003-01-14 ターガセプト，インコーポレイテッド 医薬組成物およびその使用法
AU6497200A (en) * 1999-07-30 2001-02-19 Vertex Pharmaceuticals Incorporated Acyclic and cyclic amine derivatives
AU2001257449A1 (en) * 2000-05-01 2001-11-12 Targacept, Inc. Imaging of nicotinic acetylcholine receptor subtypes
FR2847578A1 (fr) * 2002-11-21 2004-05-28 Rhodia Chimie Sa Composes amines porteurs d'au moins un allyle et d'un difluoromethyle et procede utile a leur synthese
FR2838436A1 (fr) * 2002-04-16 2003-10-17 Rhodia Chimie Sa Composes amines porteurs d'au moins un allyle et d'un difluoromethyle et procede utile a leur synthese
EP1494994A2 (fr) * 2002-04-16 2005-01-12 Rhodia Chimie Composes amines porteurs d'au moins un allyle et d'un difluoromethyle et procede utile a leur synthese
CA2563023C (fr) * 2004-04-02 2012-01-24 Arterial Remodelling Technologies, Inc. Ensemble endoprothese a base de polymere
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
UA88792C2 (ru) * 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
TWI389889B (zh) * 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
EP2357174A1 (fr) 2006-05-09 2011-08-17 AstraZeneca AB Sels de (2S)-(4E)-N-méthyl-5-[(5-isopropoxy)pyridin-3-yl]-4-pentèn-2-amine
CL2007002684A1 (es) * 2006-09-15 2008-06-27 Astrazeneca Ab Targacept Inc Combinacion que comprende un antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina; composicion farmaceutica que la comprende; kit farmaceutico; y uso para tratar perjuicio cognitivo y/o trastorno psicoticos.
EP2112923A1 (fr) * 2007-01-22 2009-11-04 Targacept Inc. Administration intranasale, buccale ou sublinguale d'analogues de métanicotine
EP2647373A1 (fr) 2008-05-12 2013-10-09 Targacept, Inc. Procédés de prévention du développement d'une rétinopathie par l'administration orale d'exo-s-mecamylamine
WO2010080757A2 (fr) 2009-01-07 2010-07-15 Astrazeneca Ab Combinaisons avec un agoniste alpha-4-bêta-2 nicotinique
SG185497A1 (en) 2010-05-20 2012-12-28 Astrazeneca Ab New process for the preparation of aryl substituted olefinic amines

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965074A (en) 1985-03-05 1990-10-23 Ciba-Geigy Corporation Method of treating memory impairment
US4684654A (en) * 1985-08-14 1987-08-04 American Cyanamid Company 3-heteroalkyl-2,4-quinzaolinediones
US4927838A (en) * 1987-07-10 1990-05-22 Hoffman-La Roche Inc. Pyridine compounds which are useful in treating a disease state characterized by an excess of platelet activating factors
US4788206A (en) * 1987-07-10 1988-11-29 Hoffmann-La Roche Inc. Pentadieneamides
US4786646A (en) * 1987-07-10 1988-11-22 Hoffmann-La Roche Inc. Cyclopropylpropenamides
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US5210076A (en) 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
US5356906A (en) 1989-10-27 1994-10-18 The Du Pont Merck Pharmaceutical Company (N-phthalimidoalkyl) piperidines useful as treatments for psychosis
DE4102289A1 (de) 1991-01-26 1992-07-30 Bayer Ag Verfahren zur herstellung von (hetero)arylalk(en/in)-ylaminen und neue (hetero)arylkinylamine
ES2153360T3 (es) 1991-05-29 2001-03-01 Abbott Lab Compuestos de isoxazol e de isotiazol que mejoran las funciones de razonamiento.
US5212188A (en) 1992-03-02 1993-05-18 R. J. Reynolds Tabacco Company Method for treatment of neurodegenerative diseases
US5242935A (en) 1992-03-06 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5227391A (en) 1992-04-10 1993-07-13 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5723477A (en) 1994-11-10 1998-03-03 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5616707A (en) * 1995-01-06 1997-04-01 Crooks; Peter A. Compounds which are useful for prevention and treatment of central nervous system disorders
JP3899126B2 (ja) * 1995-01-06 2007-03-28 ターガセプト，インコーポレイテッド 中枢神経系疾患の予防及び治療のための医薬組成物
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds

Also Published As

Publication number Publication date
AU727976B2 (en) 2001-01-04
JP2000509041A (ja) 2000-07-18
EP0900200B9 (fr) 2009-10-21
DE69739142D1 (de) 2009-01-15
CA2252515A1 (fr) 1997-10-30
WO1997040011A1 (fr) 1997-10-30
PT900200E (pt) 2009-02-26
CA2252515C (fr) 2006-11-07
EP0900200B1 (fr) 2008-12-03
EP0900200A1 (fr) 1999-03-10
JP2008247903A (ja) 2008-10-16
ES2318856T4 (es) 2010-03-03
BR9708815B1 (pt) 2009-01-13
ATE416164T1 (de) 2008-12-15
ES2318856T3 (es) 2009-05-01
US20020032206A1 (en) 2002-03-14
JP4357001B2 (ja) 2009-11-04
BR9708815A (pt) 2000-01-04
US6555684B2 (en) 2003-04-29
US6603011B1 (en) 2003-08-05
DK0900200T3 (da) 2009-03-30
AU2733297A (en) 1997-11-12
EP1997806A1 (fr) 2008-12-03

Similar Documents

Publication Publication Date Title
DK0900200T3 (da) Farmaceutiske sammensætninger til forebyggelse og behandling af sygdom i centralnervesystemet
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
RU93058531A (ru) Фторалкоксибензиламинные производные азотсодержащих гетероциклов, фармацевтическая композиция, способ лечения
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
NO20000521D0 (no) 1-(N-fenylaminoalkyl)-piperazin derivater substituert i posisjon 2 på fenylringen
ES2184960T3 (es) Nuevas pirimidin-4-onas-(5,6)-heteroaril condensadas 2,3 disustituidas.
IL192287A0 (en) Pharmaceutical compositions and methods for use
ES502656A0 (es) Un procedimiento para la preparacion de nuevos derivados de 2-propanol
ATE334120T1 (de) Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems
DE69834500D1 (de) Xanthinderivative zur behandlung von hirnischämie
DK505584A (da) Administrationssaet og farmaceutiske praeparater til anvendelse dertil
DE69837322D1 (de) Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
NO864443D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive n-substituerte 3-piperidin- eller 3-pyridin-karboksylsyrederivater.
DE69300321D1 (de) Behandlung neurodegenerativer Erkrankungen.
DE3766695D1 (de) Bizyklische diphosphonat-verbindungen und arzneimittel.
ES502654A0 (es) Un procedimiento para la preparacion de nuevos derivados de 2-propanol
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
ATE151774T1 (de) Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen
DE69229436D1 (de) Verwendung von somatostatinanalogen zur behandlung von melanomen
ATE293972T1 (de) Behandlung von chronischen schmerzen
MX19761A (es) Nuevos compuestos y procedimiento para su obtencion.